Chronisch entzündliche Darmerkrankungen: State of the Art

Zusammenfassung

Morbus Crohn und Colitis ulcerosa sind die beiden Hauptvertreter chronisch entzündlicher Darmerkrankungen. Aktuelle epidemiologische Arbeiten zeigen für beide Erkrankungen eine zunehmende Inzidenz. Damit muss zum einen die Pathogenese neu betrachtet werden, zum anderen rückt der Wunsch nach einer definitiven Therapie in den Vordergrund. Mit der vorliegenden Übersicht sollen die wesentlichen Aspekte mit Hinblick auf Pathogenese, Diagnostik und Therapie dargestellt werden. Bei der Therapie wird etwas ausführlicher auf den Aspekt des Vorgehens nach Ileozökalresektion bei Morbus Crohn eingegangen, da dies einen kritischen Zeitpunkt für eine Therapiere-Evaluation darstellt. Abschließend wird ein Ausblick in die nähere Zukunft geben, welche neuen Therapien Einzug in unseren Alltag haben werden.

Abstract

Chronic inflammatory bowel diseases are mainly represented by Crohn’s disease and ulcerative colitis. Current epidemiological data indicate a rise in incidence over the last five decades in the Western world. Consequently resulting not only in the reconsideration of the pathogenesis of inflammatory bowel diseases but furthermore emphasizing the need for a curative approach. With this review we aim to provide a concise overview on pathogenesis, diagnostics as well as therapy with a particular focus on medical strategies after ileocecal resection in Crohn’s disease. In the end the near future with regard to therapeutic strategies to be introduced into daily clinical work will be described.

Schlüsselwörter

Colitis ulcerosa - Morbus Crohn - chronisch entzündliche Darmerkrankungen - Immunsuppression

Keywords

colitis, ulcerative - colorectal Surgery - Crohn’s disease - drug therapy - endoscopy, gastrointestinal - immunosuppression - inflammatory bowel disease

• Literatur

• 1 Van Assche G, Dignass A, Panes J et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27
• 2 Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353: 362-368
• 3 Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn’s disease. Gastroenterology 2006; 130: 650-656
• 4 Bergeron V, Vienne A, Sokol H et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010; 105: 2405-2411
• 5 Burisch J, Pedersen N, Čuković-Čavka S et al. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63: 588-597
• 6 Couturier-Maillard A, Secher T, Rehman A et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013; 123: 700-711
• 7 De Cruz P, Kamm MA, Prideaux L et al. Postoperative recurrent luminal Crohn’s disease: a systematic review. Inflamm Bowel Dis 2012; 18: 758-777
• 8 Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4: 28-62
• 9 Dignass A, Preiß J, Aust D et al. Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz. Z Gastroenterol 2011; 49: 1276-1341
• 10 Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
• 11 Ford AC, Achkar J-P, Khan KJ et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-616
• 12 Franke A, McGovern DPB, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010; 42: 1118-1125
• 13 Hoffmann JC, Preiss JC, Autschbach F et al. S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn”. Z Gastroenterol 2008; 46: 1094-1146
• 14 Ben-Horin S, Margalit M, Bossuyt P et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis 2010; 4: 194-198
• 15 Horsthuis K, Bipat S, Bennink RJ et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: Meta-analysis of prospective studies. Radiology 2008; 247: 64-79
• 16 Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124
• 17 Kamm MA, De Cruz P, Wright EK et al. OP023. Optimising post-operative Crohn’s disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. J Crohn´s Colitis Suppl 2014; 8: S13
• 18 Lamb CA, Mohiuddin MK, Gicquel J et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg 2009; 96: 663-674
• 19 Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol 2008; 43: 948-954
• 20 Maul J, Siegmund B. Postoperative Therapie und Remissionserhaltung bei Morbus Crohn. Gastroenterologe 2013; 8: 211-216
• 21 Mayberry JF, Lobo A, Ford AC et al. NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people. Aliment Pharmacol Ther 2013; 37: 195-203
• 22 Miao YM, Koh D-M, Amin Z et al. Ultrasound and magnetic resonance imaging assessment of active bowel segments in Crohn’s disease. Clin Radiol 2002; 57: 913-918
• 23 Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54
• 24 Mylonaki M, Langmead L, Pantes A et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. J Gastroenterol 2004; 16: 775-778
• 25 Reese GE, Lovegrove RE, Tilney HS et al. The effect of Crohn’s disease on outcomes after restorative proctocolectomy. Dis Colon Rectum 2007; 50: 239-250
• 26 Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956-963
• 27 Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621
• 28 Sandborn WJ, Gasink C, Gao L-L et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367: 1519-1528
• 29 Savarino E, Bodini G, Dulbecco P et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol 2013; 108: 1731-1742
• 30 Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI. Am J Gastroenterol 2009; 105: 162-169
• 31 Sokol H, Lay C, Seksik P et al. Analysis of bacterial bowel communities of IBD patients: What has it revealed?. Inflamm Bowel Dis 2008; 14: 858-867
• 32 Turnbaugh PJ, Ley RE, Mahowald MA et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1131